Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts

[1]  K. Shirabe,et al.  Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts , 2020, British Journal of Cancer.

[2]  K. Shirabe,et al.  Conophylline suppresses pancreatic cancer desmoplasia and cancer‐promoting cytokines produced by cancer‐associated fibroblasts , 2018, Cancer science.

[3]  Wei Zhu,et al.  Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis , 2018, Cell Death & Disease.

[4]  C. Isidoro,et al.  Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. , 2018, Cancer letters.

[5]  E. Van Cutsem,et al.  Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  L. Qin,et al.  Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin , 2018, Cell Death & Disease.

[7]  J. Alcaraz,et al.  Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients , 2017, British Journal of Cancer.

[8]  G. Storm,et al.  Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model , 2017, Scientific Reports.

[9]  J. Freeman,et al.  Downregulation of STAT3/NF‐κB potentiates gemcitabine activity in pancreatic cancer cells , 2017, Molecular carcinogenesis.

[10]  F. Notta,et al.  Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes , 2016, Molecular Cancer Research.

[11]  C. Gaggioli,et al.  Fibroblast activation in cancer: when seed fertilizes soil , 2016, Cell and Tissue Research.

[12]  S. Rose-John,et al.  Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. , 2016, Gastroenterology.

[13]  W. Chan-on,et al.  Anoikis‐resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation , 2016, Journal of hepato-biliary-pancreatic sciences.

[14]  H. Kalthoff,et al.  Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts , 2016, BMC Cancer.

[15]  I. Ng,et al.  Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. , 2016, Cell reports.

[16]  Ning Zhang,et al.  Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma , 2016, Oncotarget.

[17]  W. Seeger,et al.  Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis , 2015, Respiratory Research.

[18]  Alison Martin,et al.  Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. , 2015, Future oncology.

[19]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[20]  C. Creighton,et al.  VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 , 2014, Oncogene.

[21]  H. Kuwano,et al.  Conophylline suppresses hepatic stellate cells and attenuates thioacetamide‐induced liver fibrosis in rats , 2014, Liver international (Print).

[22]  H. Collard,et al.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[23]  B. Ryffel,et al.  Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[24]  Nishant Bhatta,et al.  Gankyrin promotes tumor growth and metastasis through activation of IL‐6/STAT3 signaling in human cholangiocarcinoma , 2014, Hepatology.

[25]  K. Boudjema,et al.  Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma , 2013, Hepatology.

[26]  R. Fiorotto,et al.  Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma , 2013, Hepatology.

[27]  Martin Peifer,et al.  Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer , 2013 .

[28]  A. Dietz,et al.  Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. , 2013, Cancer research.

[29]  Z. Duan,et al.  Interleukin-6 signaling pathway in targeted therapy for cancer. , 2012, Cancer treatment reviews.

[30]  Duane H. Hamilton,et al.  Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. , 2012, Future oncology.

[31]  Y. Zhang,et al.  Interleukin-8 induces the endothelial cell migration through the Rac 1/RhoA-p38MAPK pathway. , 2012, European review for medical and pharmacological sciences.

[32]  K. Umezawa,et al.  Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. , 2012, Endocrinology.

[33]  A. Sirica.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma , 2012, Nature Reviews Gastroenterology &Hepatology.

[34]  J. Massagué,et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.

[35]  L. Rimassa,et al.  Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism , 2011, Gut.

[36]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[37]  T. Patel,et al.  Cholangiocarcinoma—controversies and challenges , 2011, Nature Reviews Gastroenterology &Hepatology.

[38]  S. Ishikawa,et al.  Hepatic Stellate Cells May Relate to Progression of Intrahepatic Cholangiocarcinoma , 2009, Annals of Surgical Oncology.

[39]  T. Suthiphongchai,et al.  Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. , 2009, Oncology reports.

[40]  J. Everhart,et al.  Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. , 2009, Gastroenterology.

[41]  M. Aljiffry,et al.  Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. , 2009, Journal of the American College of Surgeons.

[42]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[43]  Steven C Cunningham,et al.  Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution , 2007, Annals of surgery.

[44]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[45]  Hajime Isomoto,et al.  Interleukin 6 upregulates myeloid cell leukemia‐1 expression through a STAT3 pathway in cholangiocarcinoma cells , 2005, Hepatology.

[46]  G. Gores.  Cholangiocarcinoma: Current concepts and insights , 2003, Hepatology.

[47]  H. Thomas,et al.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours. , 2002, Journal of hepatology.

[48]  R. Weinberg,et al.  Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. , 2001, Experimental cell research.

[49]  Makimoto Kiyoko,et al.  Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. , 1996 .